UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital’s price objective points to a potential upside of 146.67% from the stock’s current price.

URGN has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, UroGen Pharma has a consensus rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Stock Performance

NASDAQ URGN traded down $0.11 on Wednesday, hitting $10.14. 114,478 shares of the stock were exchanged, compared to its average volume of 354,846. UroGen Pharma has a 52 week low of $9.78 and a 52 week high of $20.70. The company has a market capitalization of $237.67 million, a PE ratio of -3.21 and a beta of 1.08. The business’s fifty day moving average is $10.92 and its 200 day moving average is $12.41. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds have recently modified their holdings of URGN. KLP Kapitalforvaltning AS bought a new position in UroGen Pharma in the fourth quarter valued at about $59,000. China Universal Asset Management Co. Ltd. increased its stake in shares of UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after buying an additional 3,856 shares during the period. BNP Paribas Financial Markets raised its holdings in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after buying an additional 5,890 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma during the 4th quarter worth approximately $126,000. Finally, Intech Investment Management LLC bought a new stake in UroGen Pharma during the 3rd quarter worth approximately $155,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.